A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Candidate Vaccine (GSK2321138A) Manufactured Using a New Process in Adults and Children

NCT02207413 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1886

Enrollment

INDUSTRY

Sponsor class

Conditions

Influenza

Interventions

BIOLOGICAL: Influsplit Tetra™ vaccine produced by investigational process (IP)
BIOLOGICAL: Influsplit Tetra™ vaccine produced by licensed process (LP)

Sponsor

GlaxoSmithKline